Utilizing the immunoSEQ Assay in Clinical Trials

To date, there are no good preclinical models for HPV disease. Dr. Trimble’s lab has developed methods to query the cervical mucosal microenvironment at a molecular level, in very small human tissue specimens. Dr. Trimble’s lab has designed and conducted a series of early phase, investigator-initiated clinical trials testing immunotherapies to treat incipient malignancies caused by HPV. Insights gained from longitudinal subject-matched tissue specimens have informed the design and choice of vaccine for each subsequent clinical trial. Data derived from longitudinal, prospectively-obtained, subject-matched specimens obtained from their protocol participants will be discussed.

Key-Takeaways (what you will learn):
  • Understand the opportunities presented by an informative proof-of-principle clinical trial studies
  • Understand the current technical challenges of obtaining representative single-cell data from solid tumors
  • Understand strategies of biomarker development
  • Share experience using the immunoSEQ Aassay for clinical trial studies
immunoSEQ Assay is Research Use Only. Not for use in diagnostic procedures
  • Academic researchers doing clinical trials
  • Pharma companies doing/interested in clinical trials
  • Infectious disease researchers
  • Those studying/interested in immunosequencing clinical trials
watch now
Watch the webinar on demand
Connie Trimble

Connie Trimble, MD

Professor, Johns Hopkins University School of Medicine

Dr. Connie Trimble is a clinician scientist, with expertise in gynecologic pathology, clinical gynecology, and tumor immunology. Her research and patient care focus is on developing therapies to intercept malignancies attributable to human papillomavirus (HPV)./p>

Patrick Raber

Patrick Raber, Phd

Senior Manager, Research and Business Development, Adaptive Biotechnologies

Dr. Patrick Raber is an immunologist with 12 years of research experience and is an expert in the field of immunosequencing. His current role at Adaptive Biotechnologies centers in the incorporation of immunosequencing into translational research and clinical trials for Adaptive’s academic research and biopharmaceutical partners focusing on the key elements of experimental design, data analysis and data interpretation.

Arsalan Arif

arsalan arif

Founder & CEO, Endpoints News

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.